Back Hepatitis C

Hepatitis C

EASL 2017: Direct-Acting Antivirals for Hepatitis C Not Linked to Higher Liver Cancer Risk

Hepatitis C patients treated with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher rates seen in some studies are attributable to risk factors such as older age and more advanced liver disease, according to a set of studies presented at the EASL International Liver Congress this week in Amsterdam.

alt

CROI 2017: Hepatitis C Treatment Can Be Provided Successfully at Syringe Exchange Sites

Administering direct-acting antiviral therapy for people who inject drugs at a syringe exchange site led to high sustained response rates in a pilot study in New York City, researchers reported at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Expanding treatment for this population could reduce hepatitis C virus (HCV) transmission and ultimately help eliminate hepatitis C as a public health threat.

alt

CROI 2017: New HCV Infections Among HIV+ Gay Men Drop By Half After DAA Roll-Out in Netherlands

A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals (DAAs) for the hepatitis C treatment, researchers have already seen a dramatic decline in acute HCV infections among one at-risk population, HIV-positive men who have sex with men, according to findings reported at the Conference on Retroviruses and Opportunistic Infections this week in Seattle. 

alt

BHIVA 2017: London Data Shows Hepatitis C Is Transmitted During Anal Sex Without Condoms

Around 1 in 5 HIV-positive gay men who recently acquired hepatitis C virus (HCV) report anal sex without a condom as the only behavior that could explain their infection. At the same time, a third of people acquiring HCV were gay men who did not have HIV, clinicians from the Mortimer Market Centre in London reported at the British HIV Association (BHIVA) conference last week in Liverpool. The data suggest that prevention messages around sexually transmitted hepatitis C need to change.

alt

CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?

HIV/HCV coinfected people who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular carcinoma (HCC), according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

alt

FDA Approves Harvoni and Sovaldi for Adolescents with Hepatitis C

The U.S. Food and Drug Administration (FDA) on April 7 approved the first direct-acting antivirals for the treatment of chronic hepatitis C virus (HCV) infection in adolescents age 12 to 17 years. Sofosbuvir/ledipasvir (Harvoni) is now indicated for adolescents with HCV genotypes 1, 4, 5, or 6, while sofosbuvir (Sovaldi) plus ribavirin is approved for those with genotypes 2 or 3.

alt

Coverage of the 2016 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2016 Liver Meeting, annual conference of the American Association for the Study of Liver Diseases, AASLD), November 11-15, 2016, in Boston.alt

CROI 2017: Glecaprevir/ Pibrentasvir for HCV Can Be Safely Administered with Common Antiretrovirals

AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for HIV/HCV coinfected people, according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

alt

AASLD 2016: Is DAA Treatment for Hepatitis C Reducing the Need for Liver Transplants?

Patients successfully treated for hepatitis are less likely to need liver transplants and less likely to die while on a transplant waiting list, according to studies presented at the recent AASLD Liver Meeting. A related analysis looked at the optimal timing of treatment for people awaiting transplants in order to avoid "MELD purgatory."

alt